MBBP Client Allegro Diagnostics will begin marketing a “microarray-based test” for early-stage lung cancer. Allegro CEO Dan Rippy intends to offer a test called BronchoGen as a unique service through its clinical laboratory. BronchoGen is an 80-gene biomarker assay that can detect and rule out the presence of cancer cells. This screening will complement bronchoscopy, a procedure in which a clinician examines a patients airways with a scope in order to rule out the presence of cancer. Rippy hopes BronchoGen will be available by the end of 2010.
For the full article, please see GenomeWeb Daily News.
For more information on BronchoGen, please visit Allegro Diagnosics.